Tempest Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.30 Insider Own3.28% Shs Outstand11.57M Perf Week-26.84%
Market Cap19.57M Forward P/E- EPS next Y-3.49 Insider Trans- Shs Float10.08M Perf Month-32.13%
Income-33.50M PEG- EPS next Q-0.80 Inst Own72.20% Short Float0.24% Perf Quarter-26.20%
Sales- P/S- EPS this Y74.20% Inst Trans97.67% Short Ratio0.83 Perf Half Y-55.64%
Book/sh3.02 P/B0.56 EPS next Y0.90% ROA-48.20% Target Price17.67 Perf Year-88.38%
Cash/sh- P/C- EPS next 5Y- ROE-93.20% 52W Range1.66 - 15.50 Perf YTD-67.99%
Dividend- P/FCF- EPS past 5Y58.10% ROI- 52W High-88.32% Beta0.44
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low9.04% ATR0.23
Employees17 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)35.92 Volatility11.98% 9.81%
OptionableNo Debt/Eq0.44 EPS Q/Q89.60% Profit Margin- Rel Volume1.08 Prev Close1.69
ShortableYes LT Debt/Eq0.38 Earnings- Payout- Avg Volume29.03K Price1.81
Recom1.50 SMA20-18.96% SMA50-21.29% SMA200-43.87% Volume9,787 Change7.10%
Sep-07-22 08:00AM
Aug-15-22 08:00AM
Jul-07-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 04:05PM
May-26-22 04:57PM
May-13-22 08:00AM
Apr-27-22 10:01AM
Apr-08-22 01:00PM
Mar-29-22 04:00PM
Mar-10-22 08:00AM
Mar-08-22 04:30PM
Feb-09-22 08:00AM
Nov-18-21 08:00AM
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-01-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 08:00AM
Sep-09-21 04:01PM
Aug-12-21 04:01PM
Aug-09-21 08:00AM
Jul-09-21 08:00AM
Jul-01-21 04:00PM
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Woiwode ThomasDirectorApr 29Buy2.362,118,6445,000,0002,118,644May 03 05:49 PM
Dubensky Thomas W.PresidentJan 07Buy4.782,0009,560113,343Jan 11 06:36 PM
Whiting SamuelChief Medical OfficerJan 06Buy4.801,7008,1681,901Jan 10 06:37 PM